News Sentiment

AKTX sentiment intelligence

Akari Therapeutics PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.88 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+33.3% over one week, +3.6% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Form 4 Akari Therapeutics PLC For: 17 July By Investing.com

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 33.3% Price confirming higher
Trend fit Trend active 3.6% over four weeks
Fair value -79.9% Below fair value
Market Dynamics buy signal Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
Market source 8
Investing.com Canada 4
Quartr 3
GlobeNewswire 3
TradingView 3
simplywall.st 3
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 13
Regulatory and legal 3
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
TradingView Direct company coverage

Akari Therapeutics Consolidates Private Placement Closings; Issues 980,395 ADSs in Final Tranche

Akari Therapeutics (AKTX) has amended its Securities Purchase Agreement to consolidate the second and third closings of its private placement into a single closing on June 26, 2026. The company issued 980,395 additional ADSs (or prefunded warrants) in this final tranche, bringing

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:09
Source
TradingView
Stock Titan Direct company coverage

Akari Therapeutics (NASDAQ: AKTX) consolidates private placement closings, issues remaining ADSs

Akari Therapeutics (NASDAQ: AKTX) has amended its securities purchase agreement to combine the second and third closings of a private placement into a single consolidated closing on June 26, 2026. This private placement involves 1,470,588 unregistered American Depository Shares (

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:09
Source
Stock Titan
TradingView Direct company coverage

Akari Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AKTX)

This page on TradingView provides financial actuals and estimates for Akari Therapeutics Plc (NASDAQ: AKTX). Users can explore reported financial data and analyst estimates, across various financial statements and valuation metrics. The platform allows for comparison of actual re

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 10:40
Source
TradingView